AJKD
Original Investigation

Am J Kidney Dis. 59(1): 108-116, 2012

Erythropoiesis-Stimulating Agent Responsiveness and Mortality in Hemodialysis Patients: Results from a Cohort Study From the Dialysis Registry in Japan

Shingo Fukuma, MD,[1] Takuhiro Yamaguchi, PhD,[2] Seiji Hashimoto, MD, PhD,[3] Shigeru Nakai, MD, PhD,[3] Kunitoshi Iseki, MD, PhD,[3] Yoshiharu Tsubakihara, MD, PhD,[3] and Shunichi Fukuhara, MD[1]



Mortality can be affected by ESA responsiveness, which may include independent and interactive effects of ESA dose and hemoglobin level.

ESA responsiveness and outcomes in patients on hemodialysis

Steven Fishbane and Azzour Hazzan

Whether erythropoiesis-stimulating agents (ESAs) administered in high doses could be harmful is a subject of intense interest. A recent trial has studied the relationship between hemoglobin level, ESA dose and outcomes in Japanese patients on hemodialysis. Here, we review the findings and the possible impact on clinical anemia treatment.

Fishbane, S. & Hazzan, A. *Nat. Rev. Nephrol.* advance online publication 18 October 2011;

A recent study by Fukuma et al. has investigated the relationship between hemoglobin level, erythropoietin responsiveness and outcomes among Japanese hemodialysis patients

Featured in Nature Review